Early safety study of an investigational B cell treatment
Part of Immune system & allergy clinical trials.
This study tests an experimental drug called STR-P005 for people with diseases that affect B cells, such as certain autoimmune or blood disorders. The goal is to see if the drug is safe and if it helps reduce your disease symptoms.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be between 18 and 75 years old.
- Your B cells must have a specific marker called CD19, which will be checked with a blood test.
- Your major organs (such as kidney, liver, heart, and lungs) must be working well enough, which will be confirmed with tests.
- You should not have had any cell immunotherapy (like CAR-T) in the past, unless tests show those cells are gone and you still have B cells.
- You must stop taking certain immune-suppressing drugs for a period before joining (the study team will review your medications).
- You must not have other serious conditions, such as uncontrolled infections, recent heart problems, or other cancers (except certain cured ones).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new treatment (STR-P005) for autoimmune diseases. It aims to selectively target and deplete B cells that carry a specific marker, CD19, which may help reduce disease activity.
This early-phase trial tests an experimental drug called STR-P004 in people with certain types of B-cell lymphoma that have come back or not responded to standard treatments. The goal is to check the drug's safety and see if it helps shrink or control the lymphoma.
This trial tests a new medicine called STR-P004 for people with kidney diseases caused by the immune system attacking the kidneys. The study checks if the medicine is safe and if the body can tolerate it, which may help reduce kidney damage.
This trial tests a new drug called STR-P004 for adults with relapsed or refractory B-cell acute lymphoblastic leukemia (ALL), a type of blood cancer. The goal is to see if the drug is safe and can help shrink or control the cancer.
This trial tests a new experimental medicine (SYS6055 injection) for people with B-cell blood cancers (leukemia or lymphoma) that have come back or not responded to standard treatments. The goal is to see if it is safe and how well it works against cancer cells that have the CD19 marker.
This trial tests a new type of immunotherapy called BAFF-R CAR-T cells for people with B-cell lymphoma that has come back or not responded to treatment, and whose cancer cells do not have the CD19 protein. The treatment uses your own immune cells, modified to target and kill the lymphoma cells.
Hear when a new Relapsed/Refractory Autoimmune Diseases trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.